PREVIOTOX Testing
While immunotherapy has been a breakthrough in cancer treatment, patients often experience a new type of side effect, referred to as Immune-Related Adverse Events (irAEs). We have found that the germline genetic mutations we study at MiraKind and MiraDx can help predict a patient’s risk of irAEs from immune therapy.
Our first panel, PREVIOTOX, predicts up to a 9-fold increased risk of irAEs from treatment with anti-PD1 or anti-PDL1 therapies, and also predicts the likelihood of response to anti-PD1 or anti-PDL1 therapies.
PREVIOTOX Testing Populations
Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing. This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment, as well as the likelihood of response.
If you have questions about or are interested in partnering with us on PREVIOTOX testing, please contact us.
Interested in ordering PREVIOTOX for your patients? Please contact us.